Antibiotic use in 530 French hospitals: results from a surveillance network at hospital and ward levels in 2007

Dumartin, C.; L’Hériteau, F.; Péfau, Muriel; Bertrand, Xavier; Jarno, P.; Boussat, Sandrine; Angora, Pacôme; Lacavé, L.; Saby, Karine; Savey, Anne; Nguyen, Florence; Carbonne, A.; Rogues, Anne-Marie

doi:10.1093/jac/dkq228

Cited by 72 publications

(55 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…First, despite the extended use of AMC and TZP in areas in which CTX-M enzymes are prevalent (14,18,53), IR-CTX-Ms have never been described in clinical isolates (6). Second, several widespread CTX-Ms, such as CTX-M-15, are frequently coselected in the same bacterial host with other ␤-lactamases, as those of the OXA type (10,60), conferring variable degrees of resistance to BBLIs (32).…”

Section: Discussionmentioning

confidence: 99%

“…The pleiotropic hypothesis of niche evolution indicates that evolution toward CM-CTX-M is unlikely, as alleles increasing fitness during exposure to extendedspectrum cephalosporins will inevitably cause a regression of fitness when exposed to clavulanate and vice versa. However, double resistances might emerge as a consequence of the selection of compensatory mutations in the bla CTX-M gene (26) or by coincidental acquisition by horizontal gene transfer of CTX-M enzymes and other ␤-lactamases providing inhibitor resistance, such as bla oxa-1 (14). Although we know that the coselection of several ␤-lactamases in the same clone could confer a complex phenotype of resistance to ␤-lactams, an attractive suggestion is that the concomitant use of cephalosporins and BBLIs might be considered as a possible preventive strategy to delay or obstruct the development of both cephalosporin resistance and BBLI resistance.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

In VitroSelection of Variants Resistant to β-Lactams plus β-Lactamase Inhibitors in CTX-M β-Lactamases: Predicting theIn VivoScenario?

Ripoll

Baquero

Novais

et al. 2011

Antimicrob Agents Chemother

View full text Add to dashboard Cite

CTX-M ␤-lactamases are the most prevalent group of enzymes within the extended-spectrum ␤-lactamases (ESBL). The therapeutic options for CTX-M-carrying isolates are scarce, forcing the reexamination of the therapeutic possibilities of ␤-lactams plus ␤-lactamase inhibitors (BBLIs). Inhibitor-resistant CTX-M ␤-lactamases (IR-CTX-M) have not hitherto been described in natural isolates. In this study, 168 cultures of the hypermutagenic Escherichia coli GB20 strain carrying plasmid pBGS18 with different bla CTX-M genes were submitted to parallel experimental evolution assays in the presence of increasing concentrations of a combination of amoxicillin and clavulanate. Fourteen CTX-M ␤-lactamases belonging to the three most representative clusters (CTX-M-1, -2, and -9) and the two main phenotypes (cefotaxime resistance and cefotaximeceftazidime resistance) were studied. Three types of IR-CTX-M mutants were detected, having mutations S130G, K234R, and S237G, which are associated with different resistance patterns. The most frequently recovered mutation was S130G, which conferred the highest resistance levels to BBLIs (reaching 12 g/ml for amoxicillin-clavulanate and 96 g/ml for piperacillin-tazobactam when acquired by CTX-M-1 cluster enzymes). The S130G change also provided a clear antagonistic pleiotropy effect, strongly decreasing the enzyme's activity against all cephalosporins tested. A double mutation, S130G L169S, partially restored the resistance against cephalosporins. A complex pattern observed in CTX-M-58, carrying P167S and S130G or K234R changes, conferred ESBL and IR phenotypes simultaneously. The K234R and S237G changes had a smaller effect in providing inhibitor resistance. In summary, IR-CTX-M enzymes might evolve under exposure to BBLIs, and the probability is higher for enzymes belonging to the CTX-M-1 cluster. However, this process could be delayed by antagonistic pleiotropy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

In VitroSelection of Variants Resistant to β-Lactams plus β-Lactamase Inhibitors in CTX-M β-Lactamases: Predicting theIn VivoScenario?

Ripoll

Baquero

Novais

et al. 2011

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…According to the European Surveillance of Antimicrobial Consumption Network, systemic use of antibiotics increased to 3.4-fold in 2015, outside the hospitals in comparison to 2014 data. However, during 2011 to 2015, systemic use of antibiotics significantly increased in the hospitals and data showed this trend varied from 1.0 to 2.9 DDD (defined daily doses) per 1000 inhabitants and per day [1][2][3][4][5].…”

Section: Short Communicationmentioning

confidence: 99%

A Five Years Surveillance on Use of Antimicrobial Therapies in Biella's General Hospital (Italy): Effective Management to Reduce Antibiotic Resistance and Improve Outcome

Ussai¹,

D'Aloia²,

Laura³

et al. 2017

J Pharmacovigilance

View full text Add to dashboard Cite

“…Prekomerna upotreba antibiotika u bolnicama dovodi do nastanka i podstiče širenje rezistencije (26). Iako infekcija prouzrokovana Clostridium difficile može nastatati kao posledica korišćenja bilo kog antibiotika, najčešće je povezana sa upotrebom klindamicina, cefalosporina i fluorohinolona (27).…”

Section: Tabela Iunclassified

Rational use of antibiotics in stationary health care institution: Case study

Brkić¹,

Tasić²,

Jokić³

2015

Arh farmaciju

View full text Add to dashboard Cite

Napomena: Rad predstavlja deo specijalaističkog rada pod nazivom "Bezbednost pacijenata i upotreba antibiotika na tercijarnom nivou zdrastvene zaštite", odbranjenog na Katedri za socijalnu farmaciju i farmaceutsko zakonodavstvo Univerziteta u Beogradu-Farmaceutskog fakulteta 2014. godine. Kratak sadržajIzmeđu 25% i 50 % hospitalizovanihpacijenata prima antibiotike. Nekestudijeprocenjuju da je 25-68% antibiotika u bolnicamapropisanoneadekvatno. Ciljovograda je bio da se analiziraupotrebaantibiotika u Kliničko-bolničkomcentru "Bežanijskakosa". Za period od 2008. do 2012. godinepodaci o upotrebi antibiotika na godišnjem nivou su dobijeni iz baze podataka bolničke apoteke i izraženi kao DDD/100 postelja/dan. U toku petogodišnjeg perioda praćenja, ukupna upotreba antibiotika se kretala od 62,3do 65,6 DDD/100 postelja/dan. Najčešće propisivani antibiotici su bili cefalosporini, a zatim fluorohinoloni, peniciliniiaminoglikozidi. Ceftriakson je bio najčešće propisivani antibiotik. Ovi rezultati ističu potrebu za sprovođenjem efikasnih mera kako bi se smanjila široko rasprostranjena neadekvatna upotreba antibiotika u stacionarnim zdravstvenim ustanovama.

show abstract

Antibiotic use in 530 French hospitals: results from a surveillance network at hospital and ward levels in 2007

Abstract: This multicentre survey provided detailed information on antibiotic use in a large sample of hospitals and wards, allowing relevant comparisons and benchmarking. Analysis of consumption at the ward level should help hospitals to target practice audits to improve antibiotic use.

Cited by 72 publications

References 28 publications

In VitroSelection of Variants Resistant to β-Lactams plus β-Lactamase Inhibitors in CTX-M β-Lactamases: Predicting theIn VivoScenario?

In VitroSelection of Variants Resistant to β-Lactams plus β-Lactamase Inhibitors in CTX-M β-Lactamases: Predicting theIn VivoScenario?

A Five Years Surveillance on Use of Antimicrobial Therapies in Biella's General Hospital (Italy): Effective Management to Reduce Antibiotic Resistance and Improve Outcome

Rational use of antibiotics in stationary health care institution: Case study

Contact Info

Product

Resources

About